Lansing, MI-based superconducting accelerator technology firm Niowave has inked a long-term agreement to supply Novartis with actinium-225 (Ac-225).
The agreement will provide Novartis with a scalable supply of the medical isotope to support its growing portfolio of radioligand therapies (RLT). RLTs use a targeting component with a radioisotope to selectively target and destroy cancer cells, Niowave said. Financial terms of the agreement were not disclosed.
Niowave expects to expand its medical isotope production capacity with the construction of a new manufacturing facility in Lansing, slated to begin this year.
